Efficacy and safety of high-dose lanreotide autogel in patients with progressive pancreatic or midgut neuroendocrine tumours: CLARINET FORTE phase 2 study results
European Journal of Cancer（2021）
摘要
Image 1
更多查看译文
关键词
Neuroendocrine tumours,Receptors,Progression-free survival,Somatostatin,Lanreotide
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要